Programme of early detection of prostate cancer in male cancer care after oncological diseases (Q66352): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: EU contribution (P835): 471,263.96640000003 euro) |
(Changed an Item: Fixing rounding issue) |
||||||||||||||
| Property / EU contribution | |||||||||||||||
471,263.97 Euro
| |||||||||||||||
| Property / EU contribution: 471,263.97 Euro / rank | |||||||||||||||
Preferred rank | |||||||||||||||
| Property / EU contribution: 471,263.97 Euro / qualifier | |||||||||||||||
exchange rate to Euro: 0.04 Euro
| |||||||||||||||
| Property / EU contribution: 471,263.97 Euro / qualifier | |||||||||||||||
point in time: 10 January 2020
| |||||||||||||||
Revision as of 15:17, 22 September 2020
Project in Czech Republic financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Programme of early detection of prostate cancer in male cancer care after oncological diseases |
Project in Czech Republic financed by DG Regio |
Statements
11,781,599.16 Czech koruna
0 references
15,189,813.6 Czech koruna
0 references
77.56 percent
0 references
1 April 2018
0 references
31 March 2021
0 references
Ústav zdravotnických informací a statistiky ČR
0 references
50°4'3.86"N, 14°25'18.62"E
0 references
12800
0 references
Předmětem předkládaného projektu je pilotní projekt časného záchytu karcinomu prostaty ve skupině osob dispenzarizovaných u lékaře po předchozím onkologickém onemocnění. Jde tedy o projekt zaměřený na jasně definovanou populaci mužů. Cílem tohoto projektu je časný záchyt karcinomu prostaty pomocí screeningu PSA vedoucí k včasnému zahájení léčby a eliminaci rozvoje obtížně léčitelného metastatického onemocnění. Současně lze očekávat i snížení mortality. (Czech)
0 references
The subject of the present project is the pilot project for early detection of prostate cancer in a group of disabled doctors after cancer. It is therefore a project focused on a clearly defined male population. The aim of this project is early detection of prostate cancer by screening the PSA in order to start treatment early and avoid the development of a reversible metastatic disease. At the same time, mortality reductions can also be expected. (English)
0 references
Identifiers
CZ.03.2.63/0.0/0.0/15_039/0008167
0 references